Question - Sudden Hearing Loss
AM-111 Granted Fast-Track Designation
Asked 9 years ago Jakob Hansen 480
Auris Medical's AM-111 drug candidate has been granted fast-track designation by the FDA. The drug which is developed for the treatment of acute sudden hearing loss is currently in phase-III trials. The intratympanic therapy is being investigated in two separate trial arms - the topline results from the first treatment arm are expected by the third quarter of 2017. Read the full news release via the link below.
